(PRWEB) August 27, 2013
EnduRx Pharmaceuticals, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. EnduRx Pharmaceuticals is one company chosen to present among thirty from Colorado, Arizona, Utah, Montana, and New Mexico.
EnduRx Pharmaceuticals, Inc. is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The EnduRx Pharmaceuticals platform technology is based upon a modular, multivalent nanotechnology that can be designed to selectively home to vascular tumors, clots, or wounds. The initial use of the platform is focused on the therapeutic treatment of Glioblastoma multiforme (GBM). In pre-clinical models, Endurx Pharmaceuticals’ nanosystem resulted in a 90% success rate in definitive treatment of glioblastoma. Additionally, the system has demonstrated 90% tumor volume reduction in breast cancer, with similar results in prostate cancer, and has proven ability to target a variety of solid vascular tumors. Other uses of the platform technology include atherosclerosis and clots involved in heart attack and stroke, as well as imaging potential in both cancer and cardiovascular disease. EnduRx Pharmaceuticals is currently seeking partners to utilize its proprietary technology to develop the platform in these other indications, using the company’s proof of concept experiments as a basis for development.
EnduRx Pharmaceuticals, Inc. was founded in 2011 on the basis of proprietary targeting nanoworm technology developed by Dr. Erkki Ruoslahti and his laboratory at the Sanford-Burnham Medical Research Institute ("SBMRI"). Dr. Ruoslahti is among the world's 50 most-cited researchers and an influential figure in cell biology and cancer research. Dr. Ruoslahti’s work has clarified many of the fundamental mechanisms responsible for clinically relevant problems, including tumor metastasis, blood clotting and immune cell homing. His research spawned many drug-discovery programs, some of which have resulted in FDA-approved drugs.
For more information on EnduRx Pharmaceuticals, visit the company’s website here. Information regarding ACTUS Biotechnologies may be found at the company’s website, here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.
Read the full story at http://www.prweb.com/releases/2013/8/prweb11063745.htm.
Copyright©2012 Vocus, Inc.
All rights reserved